Madeleine S A Tan1, Faraz Honarparvar2, James R Falconer1, Harendra S Parekh1, Preeti Pandey1, Dan J Siskind3,4,5. 1. School of Pharmacy, The University of Queensland, 20 Cornwall St, Woolloongabba, QLD, 4102, Australia. 2. School of Clinical Medicine, The University of Queensland, 20 Weightman St, QLD, 4006, Herston, Australia. 3. School of Clinical Medicine, The University of Queensland, 20 Weightman St, QLD, 4006, Herston, Australia. d.siskind@uq.edu.au. 4. Metro South Addiction and Mental Health Service, Level 2 Mental Health, Woolloongabba Community Health Centre, 228 Logan Rd, Woolloongabba, QLD, 4102, Australia. d.siskind@uq.edu.au. 5. Princess Alexandra Hospital, 199 Ipswich Road, Woolloongabba, QLD, 4102, Australia. d.siskind@uq.edu.au.
Abstract
RATIONALE: Clozapine is the most effective antipsychotic for treatment-refractory schizophrenia for reducing positive psychotic symptoms. It is associated with a reduction in hospitalisation and overall mortality. In spite of this, clozapine remains underutilised due to its complex adverse drug reaction (ADR) profile. OBJECTIVE: This systematic review aims to investigate the association of clozapine and norclozapine serum levels, and peripheral ADRs. METHODS: Studies were searched from four electronic databases (PubMed, EMBASE, PsycINFO and CINAHL) from inception to 12 June 2020. Studies were included if they had adult patients, provided data on steady-state trough clozapine or norclozapine levels and reported on clozapine-associated ADRs. Pregnant women, case reports and series were excluded. RESULTS: A statistically significant correlation was found for clozapine serum levels and triglycerides (n = 70; r = 0.303, 95% CI 0.0119-0.546, p = 0.042), heart rate (n = 137; r = 0.269, 95% CI 0.0918-0.486, p = 0.035), and overall combined ADRs (n = 160; r = 0.264, 95% CI 0.110-0.405, p = 0.001), but not for absolute neutrophil count (n = 223; r = - 0.164, 95% CI - 0.529-0.253, p = 0.444) or total white cell count (n = 18; r = 0.0176, 95% CI - 0.203-0.237, p = 0.878). Interestingly, norclozapine serum levels were found to be statistically correlated to triglycerides (n = 120; r = 0.211, 95% CI 0.0305-0.378, p = 0.022), total cholesterol (n = 120; r = 0.272, 95% CI 0.0948-0.432, p = 0.003) and weight gain (n = 118; r = 0.208, 95% CI 0.0261-0.377, p = 0.025). CONCLUSIONS: Heart rate, triglycerides and combined ADRs are significantly correlated with clozapine levels, and triglycerides, total cholesterol and weight gain with norclozapine levels. Future prospective, randomised controlled studies are needed to identify the cause-effect relationship between clozapine levels and peripheral ADRs.
RATIONALE: Clozapine is the most effective antipsychotic for treatment-refractory schizophrenia for reducing positive psychotic symptoms. It is associated with a reduction in hospitalisation and overall mortality. In spite of this, clozapine remains underutilised due to its complex adverse drug reaction (ADR) profile. OBJECTIVE: This systematic review aims to investigate the association of clozapine and norclozapine serum levels, and peripheral ADRs. METHODS: Studies were searched from four electronic databases (PubMed, EMBASE, PsycINFO and CINAHL) from inception to 12 June 2020. Studies were included if they had adult patients, provided data on steady-state trough clozapine or norclozapine levels and reported on clozapine-associated ADRs. Pregnant women, case reports and series were excluded. RESULTS: A statistically significant correlation was found for clozapine serum levels and triglycerides (n = 70; r = 0.303, 95% CI 0.0119-0.546, p = 0.042), heart rate (n = 137; r = 0.269, 95% CI 0.0918-0.486, p = 0.035), and overall combined ADRs (n = 160; r = 0.264, 95% CI 0.110-0.405, p = 0.001), but not for absolute neutrophil count (n = 223; r = - 0.164, 95% CI - 0.529-0.253, p = 0.444) or total white cell count (n = 18; r = 0.0176, 95% CI - 0.203-0.237, p = 0.878). Interestingly, norclozapine serum levels were found to be statistically correlated to triglycerides (n = 120; r = 0.211, 95% CI 0.0305-0.378, p = 0.022), total cholesterol (n = 120; r = 0.272, 95% CI 0.0948-0.432, p = 0.003) and weight gain (n = 118; r = 0.208, 95% CI 0.0261-0.377, p = 0.025). CONCLUSIONS: Heart rate, triglycerides and combined ADRs are significantly correlated with clozapine levels, and triglycerides, total cholesterol and weight gain with norclozapine levels. Future prospective, randomised controlled studies are needed to identify the cause-effect relationship between clozapine levels and peripheral ADRs.
Entities:
Keywords:
Clozapine; Peripheral adverse drug reaction; Schizophrenia; Serum level
Authors: M W Agelink; T Majewski; C Wurthmann; K Lukas; H Ullrich; T Linka; E Klieser Journal: J Clin Psychopharmacol Date: 2001-02 Impact factor: 3.153
Authors: C J Bachmann; L Aagaard; M Bernardo; L Brandt; M Cartabia; A Clavenna; A Coma Fusté; K Furu; K Garuoliené; F Hoffmann; S Hollingworth; K F Huybrechts; L J Kalverdijk; K Kawakami; H Kieler; T Kinoshita; S C López; J E Machado-Alba; M E Machado-Duque; M Mahesri; P S Nishtala; D Piovani; J Reutfors; L K Saastamoinen; I Sato; C C M Schuiling-Veninga; Y-C Shyu; D Siskind; S Skurtveit; H Verdoux; L-J Wang; C Zara Yahni; H Zoëga; D Taylor Journal: Acta Psychiatr Scand Date: 2017-05-14 Impact factor: 6.392
Authors: Kenya A Costa-Dookhan; Sri Mahavir Agarwal; Araba Chintoh; Veronica N Tran; Nicolette Stogios; Bjørn H Ebdrup; Sanjeev Sockalingam; Tarek K Rajji; Gary J Remington; Dan Siskind; Margaret K Hahn Journal: Expert Opin Drug Saf Date: 2019-12-02 Impact factor: 4.250
Authors: F Centorrino; R J Baldessarini; J C Kando; F R Frankenburg; S A Volpicelli; J G Flood Journal: J Clin Psychopharmacol Date: 1994-04 Impact factor: 3.153
Authors: Amit Alexander; Mukta Agrawal; Ajaz Uddin; Sabahuddin Siddique; Ahmed M Shehata; Mahmoud A Shaker; Syed Ata Ur Rahman; Mohi Iqbal M Abdul; Mohamed A Shaker Journal: Int J Nanomedicine Date: 2019-07-30
Authors: Timothy David Tanzer; Thomas Brouard; Samuel Dal Pra; Nicola Warren; Michael Barras; Steve Kisely; Emily Brooks; Dan Siskind Journal: Ther Adv Psychopharmacol Date: 2022-05-24